To confirm AREG as a critical effector of the SASP, we applied cetuximab, a Food and Drug Administration (FDA)‐approved EGFR‐targeting monoclonal antibody, to treat PCa cells alongside the CM of PSC27‐BLEO. Here, AREG is linked to posterior cortical atrophy.